Litcius/Paper detail

Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality

John H. Kempen, Craig Newcomb, Terri Washington, C. Stephen Foster, Lucia Sobrin, Jennifer E. Thorne, Douglas A. Jabs, Eric B. Suhler, James T. Rosenbaum, H. Nida Sen, Grace A. Levy-Clarke, Robert B. Nussenblatt, Nirali Bhatt, Careen Y. Lowder, Debra A. Goldstein, Yannek I. Leiderman, Nisha R. Acharya, Gary N. Holland, Russell W. Read, James P. Dunn, Kurt Dreger, Pichaporn Artornsombudh, Hosne Ara Begum, Tonetta D. Fitzgerald, Srishti Kothari, Abhishek R. Payal, Ebenezer Daniel, Sapna Gangaputra, R. Oktay Kaçmaz, Teresa L. Liesegang, Siddharth S. Pujari, Naira Khachatryan, Armin Maghsoudlou, Hilkiah K. Suga, Clara M. Pak, Kathy J. Helzlsouer, Jeanine M. Buchanich

2023Ophthalmology13 citationsDOIOpen Access PDF

Topics & Concepts

MedicineInternal medicineAzathioprineHazard ratioImmunosuppressionCalcineurinPopulationStandardized mortality ratioEtanerceptCancerNational Death IndexRetrospective cohort studyInfliximabRisk of mortalitySurgeryConfidence intervalTransplantationDiseaseTumor necrosis factor alphaEnvironmental healthOcular Diseases and Behçet’s SyndromeOcular Oncology and TreatmentsIgG4-Related and Inflammatory Diseases
Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality | Litcius